Cannabis Impact on Addiction Medicine Practice

Presented by:
Dr. William Greene, M.D.
Associate Professor
University of Florida, College of Medicine

Faculty Disclosure:

Dr. Greene has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose.

Conflict of interest information for the CME Advisory Committee members can be found on the following website: . All relevant financial relationships have been mitigated.

Release Date: November 10, 2022
Expiration Date:  November 9, 2025

Target Audience: All physicians

Learning Objectives:

As a result of participation in this activity, participants should be able to:

  1. Describe cannabis-related impacts on individuals with substance use disorders.
  2. Contrast use of smoked and vaporized cannabis with traditional approved drug delivery systems.
  3. Evaluate the published data available on medical marijuana for therapeutic indications.
  4. Clarify myths associated with cannabis use in the context of the current political and legal landscape.

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resource(s) for further study:

  2. National Academies of Sciences, Engineering, and Medicine. 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, D.C.: The National Academies Press.
  3. American Psychiatric Association. Position Statement in Opposition to Cannabis as Medicine. July 2019. Available at: file:///C:/Users/susan/Downloads/Position-Cannabis-as-Medicine.pdf
  4. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health. Circulation. 2020;142:00-00. DOI: 10.1161/CIR.0000000000000883
  5. Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry. 2019; 6:995-1010.
  6. Bachhuber MA, Saloner B, and Cunningham CO. Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668-1673.
  7. Shover CL, Davis CS, Gordon SC, and Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. PNAS June 25, 2019;116(26):12624-12626.
  8. Olfson M, Wall MM, Liu S-M, and Blanco C. Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States. Am Jour Psychiatry. Jan 2018;175(1):47-53.
  9. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. AJP in Advance. doi: 10.1176/appi.ajp.2019.18101191
  10. Potency Monitoring Program, Quarterly Report #146;
  11. Forti MD, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multi-centre case-control study. The Lancet Psychiatry. 2019 May;6(5):427-436.
  12. Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. The Lancet Psychiatry. 2022 Sep;9(9):736-750. PMID: 35901795. Doi: 10.1016/S2215-0366(22)00161-4.
  14. Brubacher JR, et al. Cannabis Legalization and Detection of Tetrahydrocannabinol in Injured Drivers. NEJM Quick Take. Doi: 10.1056/NEJMsa2109371
  15. Mongeau-Perusse V, et al. Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals with Cocaine Use Disorder: Exploratory Results from a Randomized Controlled Trial.

If you have any questions please feel free to contact Nancy Boyd at (352) 594-4298 or at